Skip to main content

Table 3 Comparing different ARV exposure groups and adverse birth outcomes (ABOs)

From: Option B+ for prevention of vertical HIV transmission has no influence on adverse birth outcomes in a cross-sectional cohort in Western Uganda

Variables

Still-birth N (%) a

OR

CI 95%

P valueb

Preterm Delivery

N (%)c

OR

CI

95%

P

valueb

Small for gest. age

N (%)d

OR

CI 95%

P valueb

Any ABO

N (%)

OR

CI 95%

P valueb

Drug exposure

25

   

112

   

44

   

158

   

HIV negative

20 (6.6)

1

  

85 (28.2)

1

  

33 (11.3)

1

  

119 (39.7)

1

  

ART pre-conception

3 (7.9)

1.21

0.34–4.28

0.73e

11 (28.9)

1.04

0.49–2.18

0.93

3 (8.3)

0.71

0.21–2.46

0.78e

13 (35.1)

0.82

0.4–1.68

0.59

Option B+

2 (3.4)

0.5

0.11–2.18

0.55e

16 (27.6)

0.97

0.52–1.81

0.92

8 (13.8)

1.3

0.55–2.88

0.59

26 (44.1)

1.2

0.68–2.11

0.53

ARV regimens

5

   

27

   

11

   

39

   

ART pre-conception

3 (7.9)

1

  

11 (28.9)

1

  

3 (8.3)

1

  

13 (35.1)

1

  

Option B+

2 (3.4)

0.41

0.07–2.57

0.38e

16 (27.6)

0.94

0.38–2.32

0.89

8 (13.8)

1.76

0.44–7.12

0.52e

26 (44.1)

1.46

0.62–3.4

0.39

Drug initiationf

5

   

27

   

11

   

39

   

ARV exposure after GW 14

2 (4.3)

1

  

12 (26.7)

1

  

6 (13.3)

1

  

20 (43.5)

1

  

ARV exposure before GW 14

3 (6.0)

1.4

0.22–8.81

1e

15 (30.0)

1.18

0.48–2.89

0.72

5 (10.4)

0.76

0.21–2.67

0.66

19 (38.8)

0,82

0.36–1.87

0.64

Any ARV intake ≥90 days prior delivery

5 (6.2)

1

  

21 (26.3)

1

  

8 (10.3)

1

  

8 (53.5)

1

  

Any ARV intake <90 days prior delivery

0 (0)

0.84

0.76–0.92

1e

6 (40.0)

1.87

0.6–5.9

0.35e

3 (20.0)

0.46

0.11–1.97

0.38e

31 (38.8)

0.55

0.18–1.68

0.29

Exposure time

25

   

112

   

44

   

158

   

HIV negative

20 (6.6)

1

  

85 (28.2)

1

  

33 (11.3)

1

  

119 (39.7)

1

  

ARV exposure before GW 14

3 (6.0)

0.9

0.26–3.15

1e

15 (30.0)

1.09

0.57–2.1

0.8

5 (10.4)

0.91

0.34–2.47

0.86

19 (38.8)

0.96

0.52-1.79

0.91

Any ARV intake ≥90 days prior delivery

5 (5.2)

0.78

0.28–2.12

0.62

27 (28.4)

1.01

0.61–1.68

0.97

11 (11.8)

1.05

0.51–2.18

0.89

39 (41.1)

1.06

0.66–1.69

0.81

PMTCT intake prior delivery in days, Median (range)

135

(126–144)

  

0.86g

113,5

(14–278)

  

0.6g

125

(19–232)

  

0.73g

129 (14–278)

  

0.71g

  1. aTotal SB: 26; number excludes one woman who was on Option A at the time of delivery
  2. ball data are bivariate, Pearson’s X2 asymptotic two- sided p- value, apart from where indicated differently
  3. cTotal PTD: 116; number excludes three women on Option A and one HIV positive woman without ARV treatment
  4. dTotal SGA: 47; number excludes two women on Option A and one woman with undocumented PMTCT regimen
  5. eBivariate Fisher’s Exact test two- sided p- value
  6. fOne woman on Option B+ excluded due to missing drug initiation date
  7. gMann–Whitney-U Test
Back to article page

BMC Pregnancy and Childbirth

ISSN: 1471-2393

Contact us